|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/15/24 60 Degrees Pharmaceuticals, Inc. 8-K:8,9 3/15/24 12:277K EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: 8-K Current Report HTML 29K
2: EX-99.1 Press Release of 60 Degrees Pharmaceuticals, Inc. HTML 34K
Dated as of March 14, 2024
7: R1 Cover HTML 50K
9: XML IDEA XML File -- Filing Summary XML 12K
12: XML XBRL Instance -- ea0201831-8k_60degree_htm XML 21K
8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
4: EX-101.DEF XBRL Definitions -- sxtp-20240315_def XML 74K
5: EX-101.LAB XBRL Labels -- sxtp-20240315_lab XML 103K
6: EX-101.PRE XBRL Presentations -- sxtp-20240315_pre XML 71K
3: EX-101.SCH XBRL Schema -- sxtp-20240315 XSD 14K
10: JSON XBRL Instance as JSON Data -- MetaLinks 27± 36K
11: ZIP XBRL Zipped Folder -- 0001213900-24-022736-xbrl Zip 27K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
i 60 DEGREES PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| i Delaware | i 001-41719 | i 45-2406880 | ||
| (State or other jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification Number) |
| i 1025 Connecticut Avenue NW Suite 1000, i Washington, D.C. | i 20036 | |
| (Address of registrant’s principal executive office) | (Zip code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| The Stock Market LLC | ||||
| The Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐
Item 8.01. Other Events.
On March 15, 2024, 60 Degrees Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration informed the Company that it intends to respond to the Company’s Tafenoquine-Babesiosis Trial Protocol Submission in April 2024 rather than in March 2024 as initially anticipated. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information set forth under this Item 8.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
| Exhibit No. | Description | |
| 99.1 | Press Release of 60 Degrees Pharmaceuticals, Inc. dated as of March 14, 2024. | |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| 60 DEGREES PHARMACEUTICALS, INC. | ||
| Date: March 15, 2024 | By: | /s/ Geoffrey Dow |
| Name: | Geoffrey Dow | |
| Title: | Chief Executive Officer and President | |
2
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of / For Period end: | 3/15/24 | None on these Dates | ||
| Filed on: | 3/14/24 | |||
| List all Filings | ||||